Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
Athanassiou-Metaxa
M
M
Tzimouli
V
V
Economou
M
M
Taparkou
A
A
Tourkantoni
N
N
Kanakoudi-Tsakalidou
F
F
D000293:Adolescent; D000328:Adult; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D016130:Immunophenotyping; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000276:immunology*
D002614:Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine